HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Ranitidine bismuth citrate in the treatment of Helicobacter pylori infection.

AbstractOBJECTIVE:
Examine the effectiveness of treatments that include ranitidine bismuth citrate (RBC) for Helicobacter pylori infection.
DESIGN:
Prospective and randomised study.
PATIENTS AND METHOD:
137 patients were included (62 women, 75 males, average age 46.9 +/- 13) diagnosed with peptic ulcer and infection by Helicobacter pylori. None had received treatment previously. 67 patients were treated with RBC 400 mg bd and clarithromycin 500 mg bd for 14 days, and 70 patients with RBC 400 mg bd, clarithromycin 500 mg bd and amoxycillin 1 g bd for 7 days. The infection eradication was proven eight weeks after treatment end. The efficacy of treatment was evaluated using the intention-to-treat method. The Chisquare test (chi 2) was used for the statistical analysis of data.
RESULTS:
Infection in 48 out of 67 patients (71.64%) treated with RBC-clarithromycin for 14 days was eradicated, versus 88.57% (62 out of 70) among those treated with RBC-clarithromycin-amoxycillin for 7 days, with a significant difference between both regimens (p < 0.05).
CONCLUSIONS:
7-day treatment with RBC-clarithromycin-amoxycillin has a good eradication rate (88.57%) and represents a valid alternative to regimens including a PPI and two antibiotics, as both regimens have a similar efficacy. Results obtained with the double therapy of RBC-clarithromycin for 14 days were not satisfactory, the rate of eradication being 71.64%. The use of an RBC treatment for Helicobacter pylori infection should always be accompanied by two antibiotics in a triple therapy.
AuthorsP Hergueta Delgado, M Rojas Feria, R Romero Castro, F J Mendoza Olivares, B Gómez Rodríguez, F J Pellicer Bautista, J M Herrerías Gutiérrez
JournalRevista espanola de enfermedades digestivas : organo oficial de la Sociedad Espanola de Patologia Digestiva (Rev Esp Enferm Dig) Vol. 94 Issue 1 Pg. 19-24 (Jan 2002) ISSN: 1130-0108 [Print] Spain
PMID12073665 (Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial)
Chemical References
  • ranitidine bismuth citrate
  • Ranitidine
  • Bismuth
Topics
  • Bismuth (therapeutic use)
  • Female
  • Helicobacter Infections (drug therapy)
  • Helicobacter pylori
  • Humans
  • Male
  • Middle Aged
  • Prospective Studies
  • Ranitidine (analogs & derivatives, therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: